CD133

[Cancer Immunology Immunotherapy] Cisplatin and anti-CD133 chimeric antigen receptor T (CAR-T) combination treatment inhibited tumor progression in three different xenograft models with diminished CD133 positive stem cell-like cell infiltration.

[Oncogenesis] Researchers investigated the effects of Bruton’s tyrosine kinase (BTK) on oncurrent chemoradiotherapy-resistant oral squamous cell carcinoma tissues (OSCC). The effect of ibrutinib, a first-in-class BTK inhibitor, was tested on stem cell-like OSCC tumorspheres.

[Biomedicine & Pharmacotherapy] Scientists checked the combined effect of CD133 siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of olorectal cancer cells in the HT-29 cell line.

[Cancer Immunology Immunotherapy] Mechanistic investigations indicated that TGF-β acted on cancer cells to induce the core cancer stem cell-related genes CD133, SOX2, NESTIN, MUSASHI1 and ALDH1A expression and spheres formation via NF-κB–IL6–STAT3 signaling pathway, resulting in the increased cancer stemness and tumorigenic potential.

[Molecular Carcinogenesis] Scientists investigated the cancer stem cell‐promoting effect of factors released from myofibroblasts into the microenvironment of early colorectal cancer tumors and its molecular mechanism.

[Scientific Reports] Scientists engineered a closed-loop fluidic system to analyze molecular changes induced by variations in flow rate and pressure on primary tumor-derived lung adenocarcinoma cells.